ArticleInternational journal of nanomedicine2025
Local M1 Macrophage Reprogramming with Gluconic Acid-Coated Selenium Nanoparticles.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Bioactive Selenium Nanoparticles to Multifunctional Dermatological Platforms: Mechanism-Guided Design and Translational Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: While reprogramming tumor-associated macrophages (TAMs) using cytokines shows promise for cancer therapy, its clinical translation is limited by poor bioavailability. Essential mineral selenium (Se), via selenoproteins, is crucial for innate immunity and adaptive immunity regulation. Methods: Addressing the need for safer, more effective methods to enhance macrophage function, we leveraged the essential mineral Se to create gluconic acid-coated Se nanoparticles (GA-SeNPs). The in vivo efficacy of GA-SeNPs was assessed via intratumoral injection in a B16-F10 melanoma BALB/c mouse model, mirroring the administration route of the first virotherapy for advanced melanoma. Results: These nanoparticles successfully induced M2-to-M1 macrophage repolarization and inhibited cancer cell growth through reactive oxygen species (ROS) generation. We confirmed through transcriptomic analysis that GA-SeNPs influence the genes of key components in the biosynthesis of selenoproteins. Additionally, GA-SeNPs influence oxidative phosphorylation, inflammatory, and ribosome pathways by promoting the shift of M2 macrophages to an M1 phenotype. Crucially, in a melanoma mouse model, GA-SeNPs treatment yielded a >4-fold tumor weight reduction and effectively repolarized TAMs to an M1 phenotype while maintaining TAMs levels. GA-SeNPs inhibit cancer growth in vivo by disrupting the immunosuppressive tumor microenvironment. They maintain total TAM counts while strongly promoting M2-to-M1 repolarization. Conclusion: Their dual localization within both TAMs and cancer cells further highlights their therapeutic potential, presenting a promising strategy to advance TAM-based cancer therapies and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.